Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HEXB | P07686 | 7/20 | 0.58 |
| ▸ | OGA | O60502 | 5/20 | 0.58 |
| ▸ | HEXA | P06865 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | FEN1 | P39748 | 1/20 | 0.55 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.55 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9093307 | 0.95 | SIRT1 (0.60) | SIRT1KDM4EALDH1A1LMNAHEXB | |
| SCHEMBL9091826 | 0.92 | KDM4E (0.59) | SIRT1KDM4EALDH1A1LMNAHEXB | |
| SCHEMBL12660341 | 0.84 | SIRT1 (0.48) | SIRT1KDM4EALDH1A1LMNAHEXB | |
| SCHEMBL8395399 | 0.84 | SIRT1 (0.66) | SIRT1ALDH1A1LMNAHEXBOGA | |
| SCHEMBL8626645 | 0.84 | SIRT1 (0.66) | SIRT1KDM4EALDH1A1LMNAHEXB | |
| SCHEMBL12660542 | 0.84 | SIRT1 (0.66) | SIRT1KDM4EALDH1A1HEXBOGA | |
| SCHEMBL11629372 | 0.81 | KDM4E (0.70) | KDM4EALDH1A1LMNAHPGDPOLB | |
| SCHEMBL6887733 | 0.81 | ALDH1A1 (0.74) | KDM4EALDH1A1LMNAHPGDPOLB | |
| SCHEMBL12660543 | 0.81 | MEN1 (0.63) | SIRT1KDM4EALDH1A1LMNAHEXB | |
| SCHEMBL7735555 | 0.80 | KDM4E (0.68) | KDM4EALDH1A1LMNAHEXBHEXA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| WO-2007064345-A9 | HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE | GENENTECH INC (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| US-5981753-A | Bis-naphthalimides for the treatment of cancer | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| EP-0714387-B1 | NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER | BASF AG (DE) | 1998-05-27 | — | — | EP | disclosed |
| US-5616589-A | Bis-naphthalimides for the treatment of cancer | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-01 | — | — | US | disclosed |
| EP-0714387-A1 | NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005365-A1 | NEW BIS-NAPHTHALIMIDES FOR THE TREATMENT OF CANCER | BASF AKTIENGESELLSCHAFT (DE) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | SIRT1 2328/4885KDM4E 2365/4885ALDH1A1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.